Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gerd Rosenkranz

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Journal of Biopharmaceutical Statistics|January 31, 2006
A note on ethnic sensitivity studiesMichaela Glasbrenner, Gerd Rosenkranz
Journal of Biopharmaceutical Statistics|July 10, 2018
Methods for the analysis of multiple endpoints in small populations: A reviewRobin Ristl, Susanne Urach, Gerd Rosenkranz, et al.
Pharmaceutical Statistics|December 29, 2018
Subgroup analysis and interpretation for phase 3 confirmatory trials: White paper of the EFSPI/PSI working group on subgroup analysisAaron Dane, Amy Spencer, Gerd Rosenkranz, et al.
Scientific Reports|November 20, 2018
Mavoglurant in Fragile X Syndrome: Results of two open-label, extension trials in adults and adolescentsRandi Hagerman, Sebastien Jacquemont, Elizabeth Berry-Kravis, et al.
Journal of Neurodevelopmental Disorders|February 9, 2016
Mavoglurant in adolescents with fragile X syndrome: analysis of Clinical Global Impression-Improvement source data from a double-blind therapeutic study followed by an open-label, long-term extension studyDonald B Bailey, Elizabeth Berry-Kravis, Anne Wheeler, et al.
Orphanet Journal of Rare Diseases|November 14, 2018
Applicability and added value of novel methods to improve drug development in rare diseasesMarian Mitroiu, Katrien Oude Rengerink, Caridad Pontes, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Journal of Biopharmaceutical Statistics|January 31, 2006
A note on ethnic sensitivity studiesMichaela Glasbrenner, Gerd Rosenkranz
Journal of Biopharmaceutical Statistics|July 10, 2018
Methods for the analysis of multiple endpoints in small populations: A reviewRobin Ristl, Susanne Urach, Gerd Rosenkranz, et al.
Pharmaceutical Statistics|December 29, 2018
Subgroup analysis and interpretation for phase 3 confirmatory trials: White paper of the EFSPI/PSI working group on subgroup analysisAaron Dane, Amy Spencer, Gerd Rosenkranz, et al.
Scientific Reports|November 20, 2018
Mavoglurant in Fragile X Syndrome: Results of two open-label, extension trials in adults and adolescentsRandi Hagerman, Sebastien Jacquemont, Elizabeth Berry-Kravis, et al.
Journal of Neurodevelopmental Disorders|February 9, 2016
Mavoglurant in adolescents with fragile X syndrome: analysis of Clinical Global Impression-Improvement source data from a double-blind therapeutic study followed by an open-label, long-term extension studyDonald B Bailey, Elizabeth Berry-Kravis, Anne Wheeler, et al.
Orphanet Journal of Rare Diseases|November 14, 2018
Applicability and added value of novel methods to improve drug development in rare diseasesMarian Mitroiu, Katrien Oude Rengerink, Caridad Pontes, et al.
Pageof 1